Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state
This study utilized virtual population simulations to characterize the prolonged tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine following discontinuation during early pregnancy, revealing that maternal drug levels persist for several months postpartum and fall below therapeutic thresholds only after gestation week 33, thereby highlighting the need for strategies to mitigate risks associated with discontinuation in this population.